Xcout IntelAutolus Therapeutics plc
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Subscribe to see Autolus Therapeutics plc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Autolus Therapeutics plc at a glance
Autolus Therapeutics plc is a biotech company headquartered in London, United Kingdom, founded in 2018. It is publicly listed (AUTL) with a market capitalisation of $396.6M. Xcout tracks 22 named people at Autolus Therapeutics plc, including Christian Martin Itin (Chief Executive Officer & Director). Xcout recorded 1 job posting from Autolus Therapeutics plc in the last 90 days.
Autolus Therapeutics plc leadership
- Christian Martin ItinChief Executive Officer & Director
- Christopher VannSenior Vice President & Chief Operating Officer
- Robert F. DolskiSenior Vice President & Chief Financial Officer
- Miranda NevilleSenior VP & Chief Technology Officer
- Alexander SwanSenior Vice President & Chief Human Resources Officer
- Chris WilliamsSenior VP & Chief Business Development Officer
16 more named people on record for Autolus Therapeutics plc, with roles, board committees and tenure — see the full roster →
Autolus Therapeutics plc funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $53.2M | 2 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Autolus Therapeutics plc
Xcout recorded 1 job posting from Autolus Therapeutics plc in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Autolus Therapeutics plc's hiring signals →
Investors
Get Autolus Therapeutics plc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Autolus Therapeutics plc in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access